

Daiichi Sankyo brings new formulation for cancer pain treatment

12 September 2019 | News | By Manbeena Chawla

Launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets



Daiichi Sankyo Company Limited has announced it has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone Extended Release Tablets 5 mg, 10 mg, 20 mg and 40 mg NX “Daiichi Sankyo” (hereafter, new formulation).

The new formulation of oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer, contains the narcotic antagonist naloxone in order to prevent abuse.

It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

The addition of the new formulation to the company's product lineup of opioid analgesics will provide another treatment option to patients suffering from cancer pain and further enhance its contribution to healthcare in Japan.